Laboratory Of America Holdings: Tolmar Expands Research with New Illinois Facility
- Tolmar opens a new research facility at Rosalind Franklin University, enhancing its pharmaceutical research capabilities and collaboration potential.
- The Illinois laboratory expands Tolmar’s operational footprint and strengthens connections to local scientific talent in drug development.
- Tolmar's strategic move aligns with a trend of collaboration in the pharmaceutical sector, fostering innovation in specialty drug delivery solutions.
Innovation at the Forefront: Tolmar Expands Its Pharmaceutical Research Capabilities
Tolmar, Inc., a specialty pharmaceutical company renowned for its long-acting injectable drug delivery systems, has announced the opening of its new research facility within the Innovation and Research Park (IRP) at Rosalind Franklin University. This strategic move positions Tolmar to leverage advanced resources and collaborations in a rapidly evolving pharmaceutical landscape. The company's focus spans critical areas such as urology, oncology, and endocrinology, underscoring its commitment to addressing significant health challenges with innovative therapeutic solutions.
The establishment of the Illinois laboratory enhances Tolmar’s operational footprint, complementing its existing facilities in Colorado. Dr. Dave Loffredo, the company's vice president of innovation, emphasizes the exciting potential for collaboration within the IRP's dynamic research environment. By integrating into this vibrant ecosystem, Tolmar aims to foster partnerships that can drive advancements in drug formulation and delivery, ultimately accelerating the development of its specialized injectables. The facility allows for a deeper connection to local scientific talent, which is critical for enhancing the company’s research capabilities.
The IRP offers a robust infrastructure, spanning 100,000 square feet and housing six dedicated research centers, including those specializing in cancer cell biology and immunology. Dr. Joseph DiMario, RFU’s Executive Vice President for Research, welcomes Tolmar into the fold, highlighting the potential for innovative collaborations that can expedite product development. As Tolmar commits to expanding its regional presence, this partnership not only augments its research capacity but also signifies a broader trend of collaboration in the life sciences sector, particularly in Lake County, which boasts a vibrant network of scientists and researchers.
In addition to expanding its research capabilities, Tolmar’s new facility in Illinois positions it strategically within a growing pharmaceutical hub. The company’s ability to tap into local expertise and state-of-the-art resources aligns with its goal of enhancing its drug development pipeline. This initiative reflects a broader movement in the pharmaceutical industry, where collaboration and innovation are essential for addressing complex medical challenges.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

